NCT07225738 A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
| NCT ID | NCT07225738 |
| Status | Recruiting |
| Phase | — |
| Sponsor | City of Hope Medical Center |
| Condition | Multiple Myeloma |
| Study Type | OBSERVATIONAL |
| Enrollment | 700 participants |
| Start Date | 2026-01-21 |
| Primary Completion | 2030-08-22 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 700 participants in total. It began in 2026-01-21 with a primary completion date of 2030-08-22.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study assesses the impact of cannabis (also commonly called marijuana, weed, or THC) use on quality of life among patients with multiple myeloma who are receiving chemotherapy. It also evaluates the potential benefits and harms of cannabis use.
Eligibility Criteria
Inclusion Criteria: * \* Documented informed consent of the participant * Age: ≥ 18 years * ECOG ≤ 3 * Ability to read and understand English * Patient must be newly diagnosed with a histologically confirmed multiple myeloma * Patients may have started first line therapies and received up to four cycles * HCP SURVEY: Documented informed consent of the participant * HCP SURVEY: Age: ≥ 18 years * HCP SURVEY: Licensed physician, physician assistant, nurse practitioner, or registered nurse * HCP SURVEY: Currently practicing in oncology or providing direct care to oncology patients * HCP SURVEY: Able to read and understand English * HCP SURVEY: Affiliation with City of Hope Exclusion Criteria: * \* Patients may not have completed five cycles of first line therapy or undergone any second line therapy * Other active malignancy * Patients may not have undergone autologous hematopoietic stem cell transplantation * Unable to comply with the study assessments * HCP SURVEY: Reports directly to study PI (Dr. Richard Lee) * HCP SURVEY: Member of the study team or involved in survey design or analysis * HCP SURVEY: Individuals with a real or perceived conflict of interest that could bias survey responses
Contact & Investigator
Richard T Lee
PRINCIPAL INVESTIGATOR
City of Hope Medical Center
Frequently Asked Questions
Who can join the NCT07225738 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Myeloma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07225738 currently recruiting?
Yes, NCT07225738 is actively recruiting participants. Visit ClinicalTrials.gov or contact City of Hope Medical Center to inquire about joining.
Where is the NCT07225738 trial being conducted?
This trial is being conducted at Goodyear, United States, Duarte, United States, Huntington Beach, United States, Irvine, United States and 7 additional locations.
Who is sponsoring the NCT07225738 clinical trial?
NCT07225738 is sponsored by City of Hope Medical Center. The principal investigator is Richard T Lee at City of Hope Medical Center. The trial plans to enroll 700 participants.